Columbia Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.29M Buy
2,889
+646
+29% +$301K 0.25% 77
2025
Q4
$1.02M Buy
2,243
+1,690
+306% +$728K 0.18% 88
2025
Q3
$217K Buy
553
+55
+11% +$23K 0.04% 159
2025
Q2
$222K Buy
+498
New +$229K 0.04% 162
2025
Q1
Sell
-802
Closed -$323K 278
2024
Q4
$323K Buy
+802
New +$372K 0.06% 161

Other funds holding VRTX

Columbia Asset Management's VRTX Position: Q1 2026 in Review

Columbia Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 29% in Q1 2026, buying an estimated $301K and bringing the position to 2,889 shares worth $1.29M. The position accounts for 0.25% of the portfolio, ranked #77.

Columbia Asset Management first reported a position in VRTX in Q4 2024 and has held it in 5 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Columbia Asset Management held 2,889 shares of Vertex Pharmaceuticals worth $1.29M as of Q1 2026.
  • Columbia Asset Management bought 646 Vertex Pharmaceuticals shares in Q1 2026, an estimated $301K.
  • Vertex Pharmaceuticals made up 0.25% of Columbia Asset Management's portfolio in Q1 2026, its #77 holding.
  • Columbia Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Columbia Asset Management's 13F filing for Q1 2026, filed 21 Apr 2026.